21 May 2013
Keywords: Biosimilars uptake, Prospects, Difficulties, Approval pathway
Article | 15 March 2012
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 March 2012
16 March 2012
20 May 2013
© 2013 thepharmaletter.com